Literature DB >> 27923719

Predicting Costs of Care for Patients With Inflammatory Bowel Diseases.

Benjamin Click1, David G Binion1, Alyce M Anderson2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27923719      PMCID： PMC5316305          DOI： 10.1016/j.cgh.2016.11.027

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  32 in total

1.  National estimates of the burden of inflammatory bowel disease among racial and ethnic groups in the United States.

Authors:  Geoffrey C Nguyen; Christopher A Chong; Rachel Y Chong
Journal:  J Crohns Colitis       Date:  2013-09-24       Impact factor: 9.071

Review 2.  The narcotic bowel syndrome: a recent update.

Authors:  Douglas Drossman; Eva Szigethy
Journal:  Am J Gastroenterol Suppl       Date:  2014-09-10

3.  The prevalence and predictors of opioid use in inflammatory bowel disease: a population-based analysis.

Authors:  Laura E Targownik; Zoann Nugent; Harminder Singh; Shawn Bugden; Charles N Bernstein
Journal:  Am J Gastroenterol       Date:  2014-09-02       Impact factor: 10.864

4.  Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.

Authors:  Julajak Limsrivilai; Ryan W Stidham; Shail M Govani; Akbar K Waljee; Wen Huang; Peter D R Higgins
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-17       Impact factor: 11.382

5.  Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort.

Authors:  M D Silverstein; E V Loftus; W J Sandborn; W J Tremaine; B G Feagan; P J Nietert; W S Harmsen; A R Zinsmeister
Journal:  Gastroenterology       Date:  1999-07       Impact factor: 22.682

6.  Psychosocial factors contributing to inflammatory bowel disease activity and health-related quality of life.

Authors:  Alejandra H Faust; Leslie F Halpern; Sharon Danoff-Burg; Raymond K Cross
Journal:  Gastroenterol Hepatol (N Y)       Date:  2012-03

7.  Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease.

Authors:  A N Ananthakrishnan; V S Gainer; R G Perez; T Cai; S-C Cheng; G Savova; P Chen; P Szolovits; Z Xia; P L De Jager; S Y Shaw; S Churchill; E W Karlson; I Kohane; R H Perlis; R M Plenge; S N Murphy; K P Liao
Journal:  Aliment Pharmacol Ther       Date:  2013-01-07       Impact factor: 8.171

8.  Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy.

Authors:  Marianne K Vester-Andersen; Michelle V Prosberg; Tine Jess; Mikael Andersson; Bo G Bengtsson; Thomas Blixt; Pia Munkholm; Flemming Bendtsen; Ida Vind
Journal:  Am J Gastroenterol       Date:  2014-03-18       Impact factor: 10.864

9.  Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype.

Authors:  Jianfei Jiang; Benjamin Click; Alyce M Anderson; Ioannis E Koutroubakis; Claudia Ramos Rivers; Jana G Hashash; Michael A Dunn; Marc Schwartz; Jason Swoger; Arthur Barrie; Miguel Regueiro; Chung-Chou H Chang; David G Binion
Journal:  Clin Transl Gastroenterol       Date:  2016-07-14       Impact factor: 4.488

10.  Opioid use is associated with decreased quality of life in patients with Crohn's disease.

Authors:  David Sanford; Patrick Thornley; Anouar Teriaky; Nilesh Chande; James Gregor
Journal:  Saudi J Gastroenterol       Date:  2014 May-Jun       Impact factor: 2.485
View more
  4 in total

1.  Diet and exercise: Clinical studies and molecular biology show that diet and other lifestyle changes have significant potential for treating metabolic diseases.

Authors:  Philip Hunter
Journal:  EMBO Rep       Date:  2019-03-12       Impact factor: 8.807

Review 2.  Strategies to Identify and Reduce Opioid Misuse Among Patients with Gastrointestinal Disorders: A Systematic Scoping Review.

Authors:  Salva N Balbale; Itishree Trivedi; Linda C O'Dwyer; Megan C McHugh; Charlesnika T Evans; Neil Jordan; Laurie A Keefer
Journal:  Dig Dis Sci       Date:  2017-08-05       Impact factor: 3.199

3.  Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro.

Authors:  Ahmed Al-Dwairi; Tamara E Alqudah; Othman Al-Shboul; Mohammad Alqudah; Ayman G Mustafa; Mahmoud A Alfaqih
Journal:  J Inflamm Res       Date:  2018-03-20

Review 4.  Can molecular stratification improve the treatment of inflammatory bowel disease?

Authors:  Claire Wang; Hannah M Baer; Daniel R Gaya; Robert J B Nibbs; Simon Milling
Journal:  Pharmacol Res       Date:  2019-09-03       Impact factor: 7.658
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.